Market Place
Sourcing Support
Intra-Cellular Reports ECNP Congress 2024 Presentations
23 Sep 2024 //
GLOBENEWSWIRE
Intra-Cellular closing in on major depression nod for Caplyta
19 Jun 2024 //
FIERCE PHARMA
Intra-Cellular Announces Positive Phase 3 Results For Lumateperone In Depression
18 Jun 2024 //
GLOBENEWSWIRE
Intra-Cellular Announces Positive Phase 3 Results for Lumateperone in MDD
16 Apr 2024 //
GLOBENEWSWIRE
Intra-Cellular Announces FDA Approval of New Dosage Strengths for CAPLYTA®
25 Apr 2022 //
GLOBENEWSWIRE
Intra-Cellular`s Caplyta gains label expansion with bipolar nod
21 Dec 2021 //
FIERCEPHARMA
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA®
20 Dec 2021 //
GLOBENEWSWIRE
Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3
27 Sep 2021 //
GLOBENEWSWIRE
CAPLYTA Schizophrenia Safety and Tolerability Profile Published in the Journal
07 Jun 2021 //
GLOBENEWSWIRE
Intra-Cellular Therapies Announces Investor Webcast Presentations Lumateperone
22 Apr 2021 //
GLOBENEWSWIRE
CAPLYTA® (lumateperone) Open-Label Safety Switching Study
21 Jan 2021 //
GLOBENEWSWIRE
Intra-Cellular Announces the Initiation of Clinical Trials for ITI-LLAI
29 Dec 2020 //
INTRACELLULARTHERAPIES
Intra-Cellular`s +74% on positive lumateperone data in bipolar patients
08 Sep 2020 //
SEEKINGALPHA
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone)
23 Mar 2020 //
BIOSPACE
Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia
20 Feb 2020 //
GLOBENEWSWIRE
Intra-Cellular nabs nod for schizophrenia drug Caplyta
24 Dec 2019 //
FIERCE PHARMA
Another Delay for Intra-Cellular as FDA Extends Review of Psych Drug
05 Aug 2019 //
XCONOMY
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.